IP Library › Granted Patent US 12,290,560
Granted Patent B2
US 12,290,560 · App. 17/312,235 · Granted May 6, 2025

Vaccine for preventing or treating congenital infection with cytomegalovirus

Inventors: Masaharu Torikai (Kumamoto, JP); Hiroaki Mori (Kumamoto, JP); Tomohiro Nishimura (Kumamoto, JP); Takahiro Katayama (Kanagawa, JP); Kohsuke Hazeyama (Kumamoto, JP); Miyuki Matsumoto (Kumamoto, JP); Hiroyuki Shimizu (Saitama, JP); Naoki Inoue (Gifu, JP)
Assignee: KM Biologics Co., Ltd.
A61K39/245A61P31/20C12N7/00A61K2039/552
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,290,560
App. No.
17/312,235
Granted
May 6, 2025
Kind
B2
Abstract

An object of the present invention is to provide an effective vaccine capable of preventing and treating congenital infection with CMV. The vaccine for preventing or treating congenital infection with cytomegalovirus (CMV) according to the present invention comprises a CMV envelope glycoprotein B (gB protein) antigen and a pentamer antigen.

Claims (4)

1. A method of preventing or treating congenital infection with HCMV in a subject, comprising administering a vaccine which comprises a modified human cytomegalovirus (HCMV) envelope glycoprotein B (gB protein) antigen and a pentamer antigen consisting of HCMV gH, gL, UL128, UL130, and UL131 to the subject, wherein the gB protein antigen is an HCMV gB protein ectodomain variant comprising the amino acid substitutions at positions 156, 157, 239, 240, 456, and 458 in the amino acid sequence set forth in SEQ ID NO:7.

2. The method according to claim 1 , wherein the modified gB protein antigen comprises the amino acid sequence set forth in SEQ ID NO: 1.

3. The method according to claim 1 , wherein the pentamer antigen is ectodomains of human cytomegalovirus (HCMV) pentamer proteins having the amino acid sequences set forth in SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6.

4. The method according to claim 3 , wherein the modified gB protein antigen comprises the amino acid sequence set forth in SEQ ID NO: 1.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 9, 2021
From: TORIKAI, MASAHARU; MORI, HIROAKI; NISHIMURA, TOMOHIRO; KATAYAMA, TAKAHIRO; HAZEYAMA, KOHSUKE; MATSUMOTO, MIYUKI; SHIMIZU, HIROYUKI; INOUE, NAOKI
To: KM BIOLOGICS CO., LTD.
Reel/Frame 056488/0831 →
Priority Claims (1)
JP 2018-230640 · Dec 10, 2018 · national
Continuity (1)
Related Publication 20220023416A1 · Jan 27, 2022
References Cited (52)
US 10064935B2 · Ciaramella et al. · 2018 [cited by applicant]
US 10111945B2 · Orlinger et al. · 2018 [cited by applicant]
US 20050164365A1 · Yonemura et al. · 2005 [cited by applicant]
US 20220023416A1 · Torikai · 2022 [cited by examiner]
CA 3075207A1 · 2019 [cited by applicant]
CA 3078207A1 · 2021 [cited by applicant]
CN 105980570A · 2016 [cited by applicant]
CN 106460010A · 2017 [cited by applicant]
CN 107075486A · 2017 [cited by applicant]
EP 3015475A1 · 2016 [cited by applicant]
JP 2017503482A · 2017 [cited by applicant]
JP 2017515503A · 2017 [cited by applicant]
WO 2003004647A1 · 2003 [cited by applicant]
WO WO2012049317 · 2012 [cited by examiner]
WO 2014005959A1 · 2014 [cited by applicant]
WO 2015082570A1 · 2015 [cited by applicant]
WO 2015170287A1 · 2015 [cited by applicant]
WO 2017153954A1 · 2017 [cited by applicant]
WO WO2019052975 · 2019 [cited by examiner]
Sequence alignment of alignment instant of SEQ ID No. 1 with Geneseq database accession No. BKL33489—2022. [cited by examiner]
Sun et al. (Journal of Bioscience. 2007; 32 (6): 1111-1118). [cited by examiner]
Sequence alignment of instant SEQ 2 with Geneseq database accession No. BFT47284—2018. [cited by examiner]
Sequence alignment of instant SEQ 3 with Geneseq database access No. BAJ75101—2013. [cited by examiner]
Sequence alignment of instant SEQ 4 with Geneseq database accession No. BFT47294—2018. [cited by examiner]
Sequence alignment of instant SEQ 5 with Geneseq database accession No. BBB52383—2014. [cited by examiner]
Sequence alignment of instant SEQ 6 with Geneseq database accession No. ADP81637—2007. [cited by examiner]
Shepp et al. (Research in virology 149.2 (1998): 109-114). [cited by examiner]
Yamaguchi et al. (Vaccine. 2023; 41: 4497-4507). [cited by examiner]
Seq alignment of aa residue substituted SEQ ID 7 with Geneseq db access No. AZV29657 in WO2012/049317, Apr. 2012. [cited by examiner]
Patent Cooperation Treaty, International Preliminary Report on Patentability issued in PCT/JP2019/047966, Jun. 24, 2021, pp. 1-7. [cited by applicant]
European Patent Office, European Search Report issued in EP 19896311.8, Sep. 21, 2022, pp. 1-9. [cited by applicant]
McVoy et al., “A Cytomegalovirus DNA Vaccine Induces Antibodies that Block Viral Entry into Fibroblasts and Epithelial Cells”, Vaccine, Dec. 16, 2015, pp. 7328-7336, vol. 33(51). [cited by applicant]
Patent Cooperation Treaty, International Search Report issued in PCT/JP2019/047966, Oct. 2, 2020, pp. 1-2. [cited by applicant]
Azuma et al., “Cytomegalovirus seropositivity in pregnant women in Japan during 1996-2009”, J Jpn Soc Perin Neon Med, 2010, pp. 1273-1279, vol. 46. [cited by applicant]
Stratton et al., “Vaccines for the 21st century: a Tool for Decisionmaking”, The National Academies Press, 2000, pp. 1-473. [cited by applicant]
Revello, M.D et al., “A Randomized Trial of Hyperimmune Globulin to Prevent Congenital Cytomegalovirus”, The New England Journal of Medicine, 2014, pp. 1316-1326, vol. 370. [cited by applicant]
Rieder et al., “Cytomegalovirus vaccine: phase II clinical trial results”, Clin Microbiol Infect, 2014, pp. 95-102, vol. 20 Suppl 5. [cited by applicant]
Yamada et al., “Characterization of the guinea pig cytomegalovirus genome locus that encodes homologs of human cytomegalovirus major immediate-early genes, UL128, and UL130”, Virology, 2009, pp. 99-106, vol. 391. [cited by applicant]
Schleiss et al., “Glycoprotein B(GB) vaccines adjuvanted with AS01 or AS02 protect female guinea pigs against cytomegalovirus (CMV) viremia and offspring mortality in a CMV-challenge model”, Vaccine, 2014, pp. 2756-2762… [cited by applicant]
Hashimoto et al., “Effects of immunization of pregnant guinea pigs with guinea pig cytomegalovirus glycoprotein B on viral spread in the placenta”, Vaccine, 2013, pp. 3199-3205, vol. 31. [cited by applicant]
Coleman et al., “A Homolog Pentameric Complex Dictates Viral Epithelial Tropism, Pathogenicity and Congenital Infection Rate in Guinea Pig Cytomegalovirus”, PLOS Pathogens, 2016, pp. 1-38, vol. 12. [cited by applicant]
Zydek et al., “HCMV Infection of Human Trophoblast Progenitor Cells of the Placenta is Neutralized by a Human Monoclonal Antibody to Glycoprotein B and Not by Antibodies to the Pentamer Complex”, Viruses, 2014, pp. 1346… [cited by applicant]
Yamada et al., “An Ex vivo culture model for placental cytomegalovirus infection using slices of Guinea pig placental issue”, Placenta, 2016, pp. 85-88, vol. 37. [cited by applicant]
Patel et al., “In Vitro Characterization of Human Cytomegalovirus-Targeting Therapeutic Monoclonal Antibodies JP538 and LJP539”, Antimicrob Agents Chemother, 2016, pp. 4961-4971, vol. 60. [cited by applicant]
Burke et al., “Crystal Structure of the Human Cytomegalovirus Glycoprotein B”, PLoS Pathog, 2015, pp. 1-21, vol. 11, e1005227. [cited by applicant]
Ciferri et al., “Structural and biochemical studies of HCMV gH/gL/gO and Pentamer reveal mutually exclusive cell entry complexes”, Proc Natl Acad Sci USA, 2015, pp. 1767-1772, vol. 112. [cited by applicant]
Kanai et al., “Re-evaluation of the genome sequence of guinea pig cytomegalovirus”, J Gen Virol, 2011, pp. 1005-1020, vol. 92(Pt 5). [cited by applicant]
Yamada et al., “Guinea pig cytomegalovirus GP129/131/133, homologues of human cytomegalovirus UL 128/130/131A, are necessary for infection of monocytes and macrophages”, J Gen Virol, 2014, pp. 1376-1382, vol. 95(Pt 6). [cited by applicant]
Chiuppesi, et al., “Vaccine-Derived Neutralizing Antibodies to the Human Cytomegalovirus gH/gL Pentamer Potently Block Primary Cytotrophoblast Infection”, Journal of Virology, 2015, pp. 11884-11898, vol. 89(23). [cited by applicant]
National Center for Biotechnology Information, “Human cytomegalovirus strain AD169 complete genome”, NCBI, Jul. 26, 2016, GenBank Accession No. X17403.1. [cited by applicant]
National Center for Biotechnology Information, “Human herpesvirus 5 strain Merlin, complete genome”, NCBI, Jul. 2, 2013, GenBank Accession No. AY446894.2. [cited by applicant]
Canadian Intellectual Property Office, Official Action issued in CA 3,121,915, Jul. 31, 2023, pp. 1-6. [cited by applicant]